Novo Nordisk Sheds 13,000 Jobs Amidst Intense Competition in Weight-Loss Drug Market
The Danish pharmaceutical giant is streamlining operations and aiming to launch new blockbuster drugs by 2030 to counter competition from Eli Lilly.
Novo Nordisk, the maker of popular weight-loss medications Wegovy and Ozempic, has reduced its workforce by 13,000 employees over the past year. This reduction includes 9,000 job cuts and an additional 4,000 positions that were left unfilled.
The move comes as the company faces significant competition in the lucrative obesity drug market, particularly from rival Eli Lilly, whose Mounjaro and Zepbound medications are gaining market share.
Novo Nordisk CEO Mike Doustdar outlined a strategic plan to investors aimed at revitalizing the company's performance. The company is focused on cost-cutting measures and navigating the upcoming patent expirations for semaglutide, the active ingredient in Wegovy and Ozempic, which are anticipated in the early 2030s.
Doustdar announced that Novo, which recently dropped "Nordisk" from its name, intends to introduce more than five new blockbuster drugs by 2030, projecting new sales of approximately £17 billion in 2035. The company also aims to reach over 60 million patients globally by 2030 and significantly scale up manufacturing to supply 15 million patients with oral obesity therapies by the end of the decade.
Despite these strategic initiatives, investor confidence has been shaken, leading to a nearly 9% drop in Novo Nordisk's share price in early trading. The stock has fallen more than 70% since its peak in mid-2024.
Analysts note that while Novo Nordisk's ambitions are substantial, the competitive landscape has intensified. Eli Lilly is perceived to have a stronger near-term pipeline momentum in the obesity sector. The market for weight-loss drugs is evolving, with factors such as convenience, tolerability, and ease of use becoming as critical as efficacy for consumers.
Analysts suggest that the current share price reflects an ongoing evolution of the investment case rather than a revolutionary shift. While there is potential for significant upside if management executes its strategy, investors may require patience to see tangible proof of progress in execution, pipeline differentiation, and competitive positioning.